First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Caicun ZhouBenjamin SolomonHerbert Ho-Fung LoongKeunchil ParkMaurice PérolEdurne ArriolaSilvia NovelloBaohui HanJianying ZhouAndrea ArdizzoniM Perez MakFernando C SantiniYasir Y ElaminAlexander DrilonJürgen WolfNalin PayakachatMinji K UhDeborah RajakumarHongmei HanTarun PuriVictoria SoldatenkovaA Bence LinBoris K LinKoichi Gotonull nullPublished in: The New England journal of medicine (2023)
fusion-positive NSCLC. (Funded by Eli Lilly and others; ClinicalTrials.gov number, NCT04194944.).